1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Recombinant Uricase Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Pegloticase
  • 1.3.3 Rasburicase
  • 1.3.4 Other
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Recombinant Uricase Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 Gout
  • 1.4.3 Cancer
  • 1.4.4 Kidney Stones
  • 1.4.5 Other
• 1.5 Global Recombinant Uricase Market Size & Forecast
  • 1.5.1 Global Recombinant Uricase Consumption Value (2021 & 2025 & 2032)
  • 1.5.2 Global Recombinant Uricase Sales Quantity (2021-2032)
  • 1.5.3 Global Recombinant Uricase Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Horizo​​n Therapeutics
  • 2.1.1 Horizo​​n Therapeutics Details
  • 2.1.2 Horizo​​n Therapeutics Major Business
  • 2.1.3 Horizo​​n Therapeutics Recombinant Uricase Product and Services
  • 2.1.4 Horizo​​n Therapeutics Recombinant Uricase Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Horizo​​n Therapeutics Recent Developments/Updates
• 2.2 Sanofi
  • 2.2.1 Sanofi Details
  • 2.2.2 Sanofi Major Business
  • 2.2.3 Sanofi Recombinant Uricase Product and Services
  • 2.2.4 Sanofi Recombinant Uricase Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Sanofi Recent Developments/Updates

3 Competitive Environment: Recombinant Uricase by Manufacturer

• 3.1 Global Recombinant Uricase Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Recombinant Uricase Revenue by Manufacturer (2021-2026)
• 3.3 Global Recombinant Uricase Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Recombinant Uricase by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Recombinant Uricase Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Recombinant Uricase Manufacturer Market Share in 2025
• 3.5 Recombinant Uricase Market: Overall Company Footprint Analysis
  • 3.5.1 Recombinant Uricase Market: Region Footprint
  • 3.5.2 Recombinant Uricase Market: Company Product Type Footprint
  • 3.5.3 Recombinant Uricase Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Recombinant Uricase Market Size by Region
  • 4.1.1 Global Recombinant Uricase Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Recombinant Uricase Consumption Value by Region (2021-2032)
  • 4.1.3 Global Recombinant Uricase Average Price by Region (2021-2032)
• 4.2 North America Recombinant Uricase Consumption Value (2021-2032)
• 4.3 Europe Recombinant Uricase Consumption Value (2021-2032)
• 4.4 Asia-Pacific Recombinant Uricase Consumption Value (2021-2032)
• 4.5 South America Recombinant Uricase Consumption Value (2021-2032)
• 4.6 Middle East & Africa Recombinant Uricase Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Recombinant Uricase Sales Quantity by Type (2021-2032)
• 5.2 Global Recombinant Uricase Consumption Value by Type (2021-2032)
• 5.3 Global Recombinant Uricase Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Recombinant Uricase Sales Quantity by Application (2021-2032)
• 6.2 Global Recombinant Uricase Consumption Value by Application (2021-2032)
• 6.3 Global Recombinant Uricase Average Price by Application (2021-2032)

7 North America

• 7.1 North America Recombinant Uricase Sales Quantity by Type (2021-2032)
• 7.2 North America Recombinant Uricase Sales Quantity by Application (2021-2032)
• 7.3 North America Recombinant Uricase Market Size by Country
  • 7.3.1 North America Recombinant Uricase Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Recombinant Uricase Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Recombinant Uricase Sales Quantity by Type (2021-2032)
• 8.2 Europe Recombinant Uricase Sales Quantity by Application (2021-2032)
• 8.3 Europe Recombinant Uricase Market Size by Country
  • 8.3.1 Europe Recombinant Uricase Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Recombinant Uricase Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Recombinant Uricase Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Recombinant Uricase Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Recombinant Uricase Market Size by Region
  • 9.3.1 Asia-Pacific Recombinant Uricase Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Recombinant Uricase Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Recombinant Uricase Sales Quantity by Type (2021-2032)
• 10.2 South America Recombinant Uricase Sales Quantity by Application (2021-2032)
• 10.3 South America Recombinant Uricase Market Size by Country
  • 10.3.1 South America Recombinant Uricase Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Recombinant Uricase Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Recombinant Uricase Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Recombinant Uricase Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Recombinant Uricase Market Size by Country
  • 11.3.1 Middle East & Africa Recombinant Uricase Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Recombinant Uricase Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Recombinant Uricase Market Drivers
• 12.2 Recombinant Uricase Market Restraints
• 12.3 Recombinant Uricase Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Recombinant Uricase and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Recombinant Uricase
• 13.3 Recombinant Uricase Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Recombinant Uricase Typical Distributors
• 14.3 Recombinant Uricase Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Recombinant Uricase market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Recombinant uricase is a synthetic form of the enzyme uricase,produced using recombinant DNA technology.Uricase also known as urate oxidase,is an enzyme that catalyzes the oxidation of uric acid into allantoin,a less toxic and more soluble compound.This process helps in reducing uric acid levels in the body.
This report is a detailed and comprehensive analysis for global Recombinant Uricase market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Uricase market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Recombinant Uricase market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Recombinant Uricase market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Recombinant Uricase market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Uricase
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Uricase market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Horizo​​n Therapeutics, Sanofi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Recombinant Uricase market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pegloticase
Rasburicase
Other
Market segment by Application
Gout
Cancer
Kidney Stones
Other
Major players covered
Horizo​​n Therapeutics
Sanofi
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Uricase product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Uricase, with price, sales quantity, revenue, and global market share of Recombinant Uricase from 2021 to 2026.
Chapter 3, the Recombinant Uricase competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Uricase breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Recombinant Uricase market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Uricase.
Chapter 14 and 15, to describe Recombinant Uricase sales channel, distributors, customers, research findings and conclusion.